Eli Lilly's stock has been performing well, with some outlets suggesting it has reached record highs. The company's clinical momentum and certain products, such as tirzepatide, may be contributing factors to its stock performance. Some analysts have made predictions about the company's future stock performance, with at least one outlet increasing its price target for the company.